Dexanabinol
Dexanabinol, also known under the designations HU-211 or ETS210, is a synthetic derivative of cannabinoids. Distinct from the majority of cannabinoid derivatives, Dexanabinol represents the "unnatural" enantiomer of the influential cannabinoid agonist HU-210. Its unique properties set it apart from the conventional effects observed with many cannabinoid compounds.
Pharmacological Action[edit]
Unlike most cannabinoids, HU-211 doesn't function as a cannabinoid receptor agonist. Instead, it exerts its effects primarily as an NMDA antagonist. As such, it doesn't mimic the typical cannabis-induced outcomes.
Neuroprotective and Anticonvulsant Properties[edit]
Dexanabinol demonstrates significant anticonvulsant and neuroprotective properties. These characteristics make it an area of keen interest in scientific research, especially in studies focusing on neural health and protection.
Therapeutic Potential[edit]
The unique properties of Dexanabinol make it a candidate for various therapeutic applications:
- Brain Injury or Stroke: Given its neuroprotective characteristics, Dexanabinol is being studied for its potential in treating conditions like brain injuries or strokes, where neural protection is crucial.
- Cancer Treatment: Preliminary research indicates potential applications of Dexanabinol in the treatment of certain types of cancers, particularly brain cancer.
- Anticonvulsant: Its anticonvulsant properties are also being explored for applications in conditions like epilepsy or other seizure-related disorders.
Clinical Trials[edit]
Dexanabinol has successfully passed the safety checks in clinical trials. It's currently undergoing Phase I trials, primarily focusing on its effectiveness and applicability in the treatment of brain cancer.
Mechanism of Action[edit]
Dexanabinol’s primary mechanism doesn't revolve around the cannabinoid receptors. Instead, its action as an NMDA antagonist has intrigued researchers, leading to multiple studies on its potential benefits.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
| Cannabinoids | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
* See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
|
 | This cannabinoid related article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
